| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031515383 |
| P356 | DOI | 10.2165/11593380-000000000-00000 |
| P698 | PubMed publication ID | 21875163 |
| P5875 | ResearchGate publication ID | 51603108 |
| P2093 | author name string | Lotte M G Steuten | |
| Maarten J Ijzerman | |||
| P2860 | cites work | A real options approach to watchful waiting: theory and an illustration. | Q40226928 |
| An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery | Q40285528 | ||
| Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems | Q40338614 | ||
| A rational framework for decision making by the National Institute For Clinical Excellence (NICE). | Q40632683 | ||
| How does cost matter in health-care discrete-choice experiments? | Q41938467 | ||
| A valid and reliable belief elicitation method for Bayesian priors | Q43238496 | ||
| Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome | Q43278531 | ||
| Early-stage valuation of medical devices: the role of developmental uncertainty. | Q43706827 | ||
| Open innovation networks between academia and industry: an imperative for breakthrough therapies | Q46106384 | ||
| Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach | Q47317953 | ||
| Early technology assessment of new medical devices | Q47961457 | ||
| Eliciting distributions to populate decision analytic models | Q48852696 | ||
| Scanning the horizon for emerging health technologies. Conclusions from a European Workshop | Q50150869 | ||
| Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra. | Q50856510 | ||
| A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain. | Q51204046 | ||
| Combining Shock Reduction Strategies to Enhance ICD Therapy: A Role for Computer Modeling | Q51646232 | ||
| The value of implementation and the value of information: combined and uneven development. | Q51893581 | ||
| The efficiency frontier approach to economic evaluation of health-care interventions. | Q53172378 | ||
| Academic relationships with industry: a new model for biomedical research. | Q53493764 | ||
| Valuing Risky Projects: Option Pricing Theory and Decision Analysis | Q56094735 | ||
| Technology roadmapping—A planning framework for evolution and revolution | Q56830395 | ||
| Modelling Downstream Effects in the Presence of Technological Change | Q57412543 | ||
| Systematic review of methods for evaluating healthcare research economic impact | Q21245519 | ||
| Pragmatic approach is effective in evidence based health care | Q22242095 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| Investment in antiviral drugs: a real options approach. | Q30381507 | ||
| Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development | Q30983599 | ||
| Public health policy decisions on medical innovations: what role can early economic evaluation play? | Q33350948 | ||
| Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review | Q33373185 | ||
| EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage | Q33541294 | ||
| Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? | Q33807304 | ||
| Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? | Q34174890 | ||
| Funding of US biomedical research, 2003-2008 | Q35053881 | ||
| Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis. | Q36160491 | ||
| Economic implications of potential changes to regulatory and reimbursement policies for medical devices | Q36293520 | ||
| Using value of information analysis to prioritise health research: some lessons from recent UK experience | Q36635492 | ||
| Emerging health technologies: informing and supporting health policy early | Q37093074 | ||
| Patient preferences for next generation neural prostheses to restore bladder function | Q37180289 | ||
| A review of health impact assessment frameworks. | Q37272241 | ||
| Evaluating "payback" on biomedical research from papers cited in clinical guidelines: applied bibliometric study | Q37326549 | ||
| Characterizing structural uncertainty in decision analytic models: a review and application of methods | Q37512493 | ||
| Review on early technology assessments of nanotechnologies in oncology | Q37525371 | ||
| Methods to elicit beliefs for Bayesian priors: a systematic review | Q37588926 | ||
| Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation | Q37768242 | ||
| Clinical trial simulation: a review | Q37770955 | ||
| A valuation of infusion therapy to preserve islet function in type 1 diabetes. | Q37780254 | ||
| Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices | Q37783679 | ||
| Horizon scanning for novel therapeutics for the treatment of prostate cancer | Q39828067 | ||
| The timing of adoption of positron emission tomography: a real options approach | Q39948619 | ||
| Reducing risk through real options in systems design: the case of architecting a maritime domain protection system. | Q40018915 | ||
| Conducting discrete choice experiments to inform healthcare decision making: a user's guide. | Q40071854 | ||
| Analysing uncertainty around costs of innovative medical technologies: the case of fibrin sealant (QUIXIL) for total knee replacement. | Q40079531 | ||
| Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. | Q40202110 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 331-347 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Applied Health Economics and Health Policy | Q15764758 |
| P1476 | title | Early assessment of medical technologies to inform product development and market access: a review of methods and applications | |
| P478 | volume | 9 |
| Q47702493 | A SYSTEMATIC APPROACH FOR ASSESSING, IN THE ABSENCE OF FULL EVIDENCE, WHETHER MULTICOMPONENT INTERVENTIONS CAN BE MORE COST-EFFECTIVE THAN SINGLE COMPONENT INTERVENTIONS. |
| Q43003152 | A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker? |
| Q96645159 | A different animal? Identifying the features of health technology assessment for developers of medical technologies |
| Q36994587 | A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis |
| Q57259767 | A method for the early health technology assessment of novel biomarker measurement in primary prevention programs |
| Q38241484 | A review of the economic tools for assessing new medical devices. |
| Q35685387 | Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA). |
| Q53599945 | Belief elicitation to populate health economic models of medical diagnostic devices in development. |
| Q52399862 | Biomaterial-driven in situ cardiovascular tissue engineering-a multi-disciplinary perspective. |
| Q38607786 | Collective intelligence for translational medicine: Crowdsourcing insights and innovation from an interdisciplinary biomedical research community |
| Q37355880 | Conceptual model for early health technology assessment of current and novel heart valve interventions. |
| Q38074916 | Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review |
| Q47586575 | Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia |
| Q35630911 | Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings |
| Q92131828 | Defining the clinician's role in early health technology assessment during medical device innovation - a systematic review |
| Q47192522 | Designing medical technology for resilience: integrating health economics and human factors approaches |
| Q47121376 | Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia |
| Q35782483 | Development of a web-based tool for the assessment of health and economic outcomes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). |
| Q47414295 | EXPLORATION AND PREFERENTIAL RANKING OF PATIENT BENEFITS OF MEDICAL DEVICES: A NEW AND GENERIC INSTRUMENT FOR HEALTH ECONOMIC ASSESSMENTS. |
| Q91464057 | Early assessment of innovation in a healthcare setting |
| Q33968510 | Early economic evaluation of emerging health technologies: protocol of a systematic review |
| Q51252930 | Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. |
| Q38637900 | Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancer |
| Q33845622 | Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature |
| Q36603368 | HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS |
| Q39004145 | Improving Evaluation to Address the Unintended Consequences of Health Information Technology:. a Position Paper from the Working Group on Technology Assessment & Quality Development. |
| Q38207115 | Improving early cycle economic evaluation of diagnostic technologies |
| Q99554825 | Linked Pharmacometric-Pharmacoeconomic Modelling and Simulation in Clinical Drug Development |
| Q38210009 | Medical devices early assessment methods: systematic literature review |
| Q36925729 | Multi-Dimensional Impact of the Public-Private Center for Translational Molecular Medicine (CTMM) in the Netherlands: Understanding New 21(st) Century Institutional Designs to Support Innovation-in-Society |
| Q38842583 | Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment |
| Q54967250 | Pharmaceutical Market Access: current state of affairs and key challenges - results of the Market Access Launch Excellence Inventory (MALEI). |
| Q91979199 | Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia |
| Q39640697 | Predicting the health economic performance of new non-fusion surgery in adolescent idiopathic scoliosis |
| Q30577041 | Public stated preferences and predicted uptake for genome-based colorectal cancer screening. |
| Q39640964 | Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations |
| Q47726481 | Review of Economic Submissions to NICE Medical Technologies Evaluation Programme. |
| Q40839705 | THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. |
| Q55315552 | The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. |
| Q38074877 | The economic evaluation of medical devices: challenges ahead |
| Q57899345 | The overarching framework of translation and integration into healthcare: a case for the LAL model |
| Q34524056 | The role of health technology assessment bodies in shaping drug development |
| Q47627144 | Towards a bioethics of innovation. |
| Q57280144 | Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product |
| Q90673702 | Understanding patients' preferences for osteoporosis treatment: the impact of patients' characteristics on subgroups and latent classes |
| Q39268332 | Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non-ST elevation myocardial infarction patients. |
| Q36162575 | Using multicriteria decision analysis to support research priority setting in biomedical translational research projects |
Search more.